Biogen Inc. Stock Underperforms Friday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) slid 1.35% to $283.63 Friday, on what proved to be an all-around poor tr
Analysts' Top Healthcare Picks: Biogen (BIIB), Cytokinetics (CYTK)
Biogen Inc. Stock Underperforms Thursday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) slid 1.40% to $287.52 Thursday, on what proved to be an all-around mixed
U.K. Pharma Lobby Urges Govt. to Halt Plans to Raise Revenue Recovery Rates
Anavex Gains as Trial for Rett Syndrome Candidate Exceeds Enrollment Target
Biogen Inc. Stock Rises Wednesday, Still Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) inched 0.24% higher to $291.60 Wednesday, on what proved to be an all-ar
Biogen Inc. Stock Rises Tuesday, Outperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Biogen Inc. (BIIB) advanced 1.73% to $290.90 Tuesday, on what proved to be an all-around po
Immunic Adds 14% as Wedbush Initiates With Bullish View on Lead Asset
UniQure Inks Licensing Deal for Gene Therapy Candidate Targeting ALS
Eisai-Biogen Gets Priority Review for Alzheimer's Drug in Japan
05:15 AM EST, 01/31/2023 (MT Newswires) -- Japanese health authorities awarded priority review status to the application filed by Eisai (TYO:4523) for the manufacturing and marketing of lecanemab, an
Loading...
No Stock Yet